To provide the information your oncologist is not telling you or doesn't have the time to!
Dive into the heart of innovation with our “Clinical Trials” subcategory, where we unveil the dynamic world of oncology research in real-time. Discover the latest developments and breakthroughs in cancer treatment as we explore ongoing clinical trials and their potential impact on patient care. Gain insights into the rigorous process of testing novel therapies, uncover promising treatment options, and learn how these trials contribute to advancing the field of oncology. Stay informed and be part of the journey towards more effective and compassionate cancer care.
I am very excited to announce the opening of a new Cellular Therapy by Tscan Therapeutics using TCR protocol at the Orlando Health Cancer Institute (OHCI) targeting Melanoma, Head/Neck Cancer, NSCLC, Ovarian, and HPV positive Anal-Cervical SCC. Information for this new open clinical trial was provided from a public source. Please reach out to Karin …
Intratumoral therapies is another class of immunotherapeutics that I often consider especially for folks with limited skin or nodal disease or perhaps deeper oligometastatic disease. I have cutaneous malignancies patients with Melanoma, Cutaneous SCC, Merkel cell and Kaposi sarcomas that have responded to local intratumoral therapies. We’ve seen viral agents like FDA approved TVEC, RP1, …
In terms of cancer diagnoses, the more common ones we hear of are cancers such as Leukemia, Lymphoma, melanoma, and breast cancer. But what about Leiomyosarcoma?
Leiomyosarcoma is a rare and aggressive form of cancer that develops in the smooth muscles of the body (i.e. intestines, stomach, uterus, blood vessels).
One of the most vivid metaphors for chemotherapy is that of a bomb: it obliterates both good and bad cells, with the hope that only the good ones regenerate. While traditional chemotherapy remains a significant tool in cancer treatment, there’s been a recent shift towards more precise therapies that selectively target cancer cells. In the …
This is a new clinical trial using Tebentafusp alone or in combination with Pembrolizumab is now open and actively enrolling at the Orlando Health Cancer Institute for patients dealing with Metastatic Cutaneous Melanoma. Tebentafusp is currently FDA approved for all patients with Metastatic Uveal Melanoma. Detailed information can be found here at clinicaltrials.gov and NEJM …
Article written by one of our Melanoma/Sarcoma Clinical Trial Coordinators Chloe Caldwell to a target audience of healthcare providers regarding a new ongoing protocol for patients dealing with GIST open globally and at the Orlando Health Cancer Institute. All information posted here is publicly available here. Gastrointestinal Stromal Tumors (GIST) constitute a category of soft …
Replaying this post as a reminder that this study is enrolling at multiple sites globally. More detailed information can also be seen here at clinicaltrials.gov as well as the sponsor Iovance. All information and data stated in this article are available publicly through online resources that I’ve also linked below for reference. This new trial …
I am really excited about this new protocol specifically for patients with MAGE4+ HLA restricted SPEAR TILs for Metastatic Melanoma, Non-small Cell Lung Cancer, Head Neck cancer, Ovarian, Endometrial, and Urothelial cancers. The Gastric and Esophageal Cancer cohorts are closed. The social media material seen here was approved both the sponsor and IRB. Please contact …
Merkel cell carcinoma (MCC) is the unsung villain of the skin cancer world – rare, aggressive, and often flying under the radar. MCC is a neuroendocrine skin cancer that usually rears its ugly head as a firm, painless nodule on sun-exposed areas of the skin. Risk factors for this sneaky skin invader include advanced age, …
New and exciting immunotherapeutic trial for multiple cancer subtypes. Article written by our senior research coordinator Karin Donaldson. Consider trials earlier in the course in patients with unresectable or metastatic cancer whenever possible. I have sponsor and IRB approval to place this article on this blog! More detail information can be found at MDNA and …